Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope
Authors:
- 1 February 2021
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 32, 116013
Abstract
No abstract availableKeywords
Funding Information
- University of Texas Health Science Center at Houston
- U.S. Department of War (W81XWH-18-1-0004, W81XWH-19-1-0598)
- Japan Society for the Promotion of Science
- Welch Foundation (AU-0042-20030616)
- California Breast Cancer Research Program
- Cancer Prevention and Research Institute of Texas (RP150551, RP190561)
- University of Texas System
This publication has 25 references indexed in Scilit:
- Antibody–drug conjugates: current status and future directionsDrug Discovery Today, 2014
- Antibody–Drug Conjugates: An Emerging Concept in Cancer TherapyAngewandte Chemie International Edition, 2014
- Site-specific antibody drug conjugates for cancer therapymAbs, 2013
- RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and DiagnosisMolecular Pharmaceutics, 2012
- Bioengineering a Unique Deimmunized Bispecific Targeted Toxin That Simultaneously Recognizes Human CD22 and CD19 Receptors in a Mouse Model of B-Cell MetastasesMolecular Cancer Therapeutics, 2010
- Folate-Immunoglobulin G as an Anticancer Therapeutic AntibodyBioconjugate Chemistry, 2010
- Radiolabeled Cyclic RGD Peptides as Integrin αvβ3-Targeted Radiotracers: Maximizing Binding Affinity via BivalencyBioconjugate Chemistry, 2009
- Sulforhodamine B colorimetric assay for cytotoxicity screeningNature Protocols, 2006
- RGD‐modified anti‐CD3 antibodies redirect cytolytic capacity of cytotoxic T lymphocytes toward αvβ3‐expressing endothelial cellsInternational Journal of Cancer, 2004
- Folate-mediated Drug Delivery: Effect of Alternative Conjugation ChemistryJournal of Drug Targeting, 1999